IPAX-1 Late Breaking Oral Presentation at the Congress of Neurological Surgeons (CNS) Meeting
19 oct. 2021 18h12 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce the first set of peer-reviewed results...
CNS Pharmaceuticals Inc. Featured in Syndicated Broadcast Covering Dosing of First Patients in Its Berubicin Clinical Development Program for Glioblastoma Multiforme
11 oct. 2021 08h00 HE
|
CNS Pharmaceuticals, Inc.
LOS ANGELES, Oct. 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for...
Philogen Provides Corporate Update
29 sept. 2021 04h58 HE
|
Philogen
Philogen Provides Corporate Update Nidlegy™ and Fibromun on track with planned timelines in pivotal clinical trialsUse of Nidlegy™ in non-melanoma skin cancer expanded in Phase II clinical...
Ivy Brain Tumor Center and SonALAsense Announce Positive Initial Results of the First-in-Human Phase 0/1 Clinical Trial of Non-Invasive Sonodynamic Therapy for Recurrent Glioblastoma
20 sept. 2021 12h00 HE
|
Ivy Brain Tumor Center
PHOENIX, Ariz., Sept. 20, 2021 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute, the largest early-phase drug development program for brain cancer in the world, and...
Curative Biotechnology, Inc. Announces Addition of Dr. Nicholas Boulis to Scientific and Clinical Advisory Board
02 sept. 2021 10h10 HE
|
Curative Biotechnology, Inc.
Company's Clinical Program for CD56 Monoclonal Antibody Drug Conjugate for Treatment of Glioblastoma to Benefit from Expertise in Neurobiology Boca Raton, FL, Sept. 02, 2021 (GLOBE NEWSWIRE) --...
Ivy Brain Tumor Center Announces Plan to Build New Global Headquarters in Phoenix
21 juil. 2021 05h00 HE
|
Ivy Brain Tumor Center
Phoenix, AZ, July 21, 2021 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute, the largest Phase 0 clinical trials program for aggressive brain tumors, announced its...
Ivy Brain Tumor Center Announces Interim Results from a Phase 0 ‘Trigger’ Trial of Targeted Combination Therapy for Glioblastoma
04 juin 2021 09h48 HE
|
Ivy Brain Tumor Center
Phoenix, AZ, June 04, 2021 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute, the largest early-phase drug development program for brain cancer in the world, has...
Brain Cancer Canada finance une recherche révolutionnaire sur le traitement du glioblastome
31 mai 2021 09h59 HE
|
Brain Cancer Canada
TORONTO, 31 mai 2021 (GLOBE NEWSWIRE) -- Le 31 mai marque la fin du mois de sensibilisation au cancer du cerveau. Ce jour-là, Brain Cancer Canada passe de la sensibilisation à l'action en soutenant...
Brain Cancer Canada Funds Groundbreaking Glioblastoma Treatment Research
31 mai 2021 09h59 HE
|
Brain Cancer Canada
TORONTO, May 31, 2021 (GLOBE NEWSWIRE) -- May 31 marks the end of Brain Cancer Awareness Month. On this day, Brain Cancer Canada turns awareness into action by emphatically supporting groundbreaking...
T.J. Stalvey Joins NX Development Corp. (NXDC) as Vice President of Clinical Development and Medical Affairs
15 avr. 2021 10h00 HE
|
NX Development Corp.
Lexington, KY, April 15, 2021 (GLOBE NEWSWIRE) -- NX Development Corp. (NXDC), a life-sciences company wholly owned by photonamic GmbH & Co. KG., today announced that Tracy Jerome “T.J.” ...